Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

• DOI: 10.1038/s41395-018-0162-0
• Publication Date: 2018-06-25T15:11:11Z
• Authors: Neeraj Narula; Farhad Peerani; Joseph Meserve; Gursimran Kochhar; Khadija Chaudrey; Justin Hartke; Prianka Chilukuri; Jenna Koliani-Pace; Adam Winters; Leah Katta; Eugenia Shmidt; Robert Hirten; David Faleck; Malav P. Parikh; Diana Whitehead; Brigid S. Boland; Siddharth Singh; Sashidhar Varma Sagi; Monika Fischer; Shannon Chang; Morris Barocas; Michelle Luo; Karen Lasch; Matthew Bohm; Dana Lukin; Keith Sultan; Arun Swaminath; David Hudesman; Nitin Gupta; Bo Shen; Sunanda Kane; Edward V. Loftus; Corey A. Siegel; Bruce E. Sands; Jean-Frederic Col...; William J. Sandborn; Parambir S. Dulai
• Keywords: Vedolizumab

We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, identify predictors response treatment.Retrospective review (May 2014-December 2016) VICTORY Consortium data. Adults with follow-up after starting VDZ clinically active UC were included. Primary outcomes cumulative rates clinical remission (resolution all UC-related symptoms) endoscopic (Mayo sub-score 0). Key secondary included corticosteroid-free deep (clinical remission). Cox proportional hazard analyses independent treatment effectiveness. Non-response imputation (NRI) sensitivity performed outcomes. serious infection, adverse events, colectomy.We 321 patients (71% prior TNFα antagonist exposure, median 10 months). The 12-month 51% 41%, respectively. Corresponding 37% 30%, Using NRI, 20% (n = 64/321) remission, 17% 35/203) 15% 30/195) 14% 28/203) remission. A majority without adequate at 12 months who deemed non-responders using NRI had already achieved 70) or a significant 36) months. discontinuation was observed in 91 patients, lack 56), need surgery 29), event 6). On multivariable analyses, exposure associated reduced probability achieving (HR 0.53, 95% CI 0.38-0.75) 0.51, 0.29-0.88). Serious events infections reported 6% 4% Overall colectomy over 13%, lower naive therapy (2%) than those been exposed antagonists (19%).In this large real-world cohort we that well tolerated effective key